Global CD62L Antibody Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global CD62L Antibody Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells.
CD62L Antibody report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD62L Antibody market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Immunochemistry (IHC) and Immunofluorescence (IF) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for CD62L Antibody industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, CD62L Antibody key companies include Thermo Fisher Scientific, Leinco Technologies, Bio-Rad, BD Biosciences, Proteintech Group, RayBiotech, Abcam, GeneTex and LifeSpan BioSciences, etc. Thermo Fisher Scientific, Leinco Technologies, Bio-Rad are top 3 players and held % share in total in 2022.
CD62L Antibody can be divided into Monoclonal and Polyclonal, etc. Monoclonal is the mainstream product in the market, accounting for % share globally in 2022.
CD62L Antibody is widely used in various fields, such as Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP) and Western Blot (WB), etc. Immunochemistry (IHC) provides greatest supports to the CD62L Antibody industry development. In 2022, global % share of CD62L Antibody went into Immunochemistry (IHC) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global CD62L Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Thermo Fisher Scientific
Leinco Technologies
Bio-Rad
BD Biosciences
Proteintech Group
RayBiotech
Abcam
GeneTex
LifeSpan BioSciences
BioLegend
Antigenix America
NSJ Bioreagents
ichorbio
Miltenyi Biotec
Cell Sciences
Abbexa
Bio X Cell
Tonbo Biosciences
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD62L Antibody market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, CD62L Antibody introduction, etc. CD62L Antibody Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of CD62L Antibody market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
CD62L Antibody report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD62L Antibody market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Immunochemistry (IHC) and Immunofluorescence (IF) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for CD62L Antibody industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, CD62L Antibody key companies include Thermo Fisher Scientific, Leinco Technologies, Bio-Rad, BD Biosciences, Proteintech Group, RayBiotech, Abcam, GeneTex and LifeSpan BioSciences, etc. Thermo Fisher Scientific, Leinco Technologies, Bio-Rad are top 3 players and held % share in total in 2022.
CD62L Antibody can be divided into Monoclonal and Polyclonal, etc. Monoclonal is the mainstream product in the market, accounting for % share globally in 2022.
CD62L Antibody is widely used in various fields, such as Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP) and Western Blot (WB), etc. Immunochemistry (IHC) provides greatest supports to the CD62L Antibody industry development. In 2022, global % share of CD62L Antibody went into Immunochemistry (IHC) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global CD62L Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Thermo Fisher Scientific
Leinco Technologies
Bio-Rad
BD Biosciences
Proteintech Group
RayBiotech
Abcam
GeneTex
LifeSpan BioSciences
BioLegend
Antigenix America
NSJ Bioreagents
ichorbio
Miltenyi Biotec
Cell Sciences
Abbexa
Bio X Cell
Tonbo Biosciences
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD62L Antibody market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, CD62L Antibody introduction, etc. CD62L Antibody Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of CD62L Antibody market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices